at this point. You agree with that. Obviously we're going to follow the restrictions. But what are your thoughts about the JAK inhibitors? The good news about psoriasis patients is that they're a little younger than our patients in rheumatoid arthritis, so we can probably get away with JAK inhibitors in the younger patients.
One more quick point I want to make is about obesity. We sometimes hesitate to discuss this with the patient because it's a touchy subject and it's shared decision-making. But you always kind of ask permission — at least I do. I ask them if we can talk about their weight, and if it is okay for me to discuss it. Because it does impact how I treat their psoriatic arthritis. Patients who are overweight or obese have problems other than that — it reduces their functional ability.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Medscape - 🏆 386. / 55 Read more »
Source: axios - 🏆 302. / 63 Read more »
Source: MedicineNet - 🏆 575. / 51 Read more »